腹腔镜与开腹胰十二指肠切除术治疗腺癌的长期肿瘤学结局相当:倾向评分加权分析
该研究比较腹腔镜胰十二指肠切除术(LPD)与开腹手术(OPD)治疗腺癌的长期肿瘤学结局,采用倾向评分加权减少选择偏倚。纳入2000年1月至2010年4月单中心87例胰十二指肠切除术患者,其中40例LPD、25例OPD为腺癌。中位随访34.5个月,倾向评分调整后LPD与OPD中位总生存分别为35.5个月与29.6个月,无复发生存分别为21.5个月与13.7个月,差异均无统计学意义。结论认为LPD长期肿瘤学安全性不劣于OPD。
要点
- 倾向评分调整后LPD与OPD总生存和无复发生存差异均无统计学意义。
- LPD组1、3、5年总生存率分别为80.5%、49.2%、39.7%,OPD组为77.8%、46.4%、30%。
- LPD组1、3、5年无复发生存率分别为70.9%、33.3%、21.9%,OPD组为62.3%、37.9%、25.7%。
核心结论
- 对于腺癌患者,LPD在长期肿瘤学结局方面不劣于OPD。
研究设计与样本
- 单中心回顾性研究,纳入2000年1月至2010年4月Institut Mutualiste Montsouris所有行胰十二指肠切除术的患者。
- 共87例患者行胰十二指肠切除术,其中40例LPD、25例OPD为确诊腺癌。
- 采用多因素logistic回归计算倾向评分,并以倾向评分加权调整Cox比例风险模型。
主要发现
- 中位随访时间34.5个月。
- 随访期间LPD组16例(40%)、OPD组7例(28%)发现转移。
- 倾向评分调整后,LPD与OPD中位总生存分别为35.5个月与29.6个月。
- LPD与OPD的1年、3年、5年总生存率分别为80.5%、49.2%、39.7%与77.8%、46.4%、30%,P值分别为0.41、0.42、0.25。
- LPD与OPD的中位无复发生存分别为21.5个月与13.7个月,1年、3年、5年无复发生存率分别为70.9%、33.3%、21.9%与62.3%、37.9%、25.7%,P值分别为0.27、0.37、0.39。
临床怎么用
- 在早期采用LPD的中心,LPD可用于腺癌患者的胰十二指肠切除术,长期肿瘤学结局与OPD相当。
局限性
- LPD处于早期开展阶段,结果可能受学习曲线影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, no study has reported long-term oncologic outcome for patients undergoing laparoscopic pancreaticoduodenectomy (LPD) compared to open surgery (OPD). The aim of this study is assess long-term oncologic outcomes for patients with adenocarcinoma undergoing LPD versus OPD using propensity score weighting modeling to minimize selection bias. PATIENTS AND METHODS: All patients undergoing PD at Institut Mutualiste Montsouris between January 2000 and April 2010 were included. Propensity scores were calculated using multivariate logistic regression, relating preoperative covariates to surgical approach. Logistic regression was performed, and Cox proportional hazards models for postoperative outcomes were constructed, with and without adjustment for propensity scores weights. RESULTS: Among 87 patients who underwent PD, 40 underwent LPD and 25 OPD for confirmed adenocarcinoma. Preoperative covariates across both groups were comparable. The median follow-up time was 34.5 months. During follow-up, metastasis was identified in 16 (40%) LPD and 7 (28%) OPD patients. After propensity score adjustment, the median overall survival (OS) was 35.5 versus 29.6 months, respectively. The 1-, 3-, and 5-year OS rates were 80.5, 49.2, 39.7% and 77.8, 46.4, 30% in the LP and OPD groups (P = 0.41, 0.42, 0.25), respectively. The median recurrence-free survival (RFS) was 21.5 versus 13.7 months (LPD vs. OPD), and the 1-, 3-, and 5-year RFS rates were 70.9, 33.3, 21.9% and 62.3, 37.9, 25.7% in the LP and OPD groups (P = 0.27, 0.37, 0.39), respectively. CONCLUSIONS: Due to the early adoption of LPD, this study is the first to report on long-term oncologic safety of LPD: LPD is non-inferior to OPD with respect to long-term outcomes for patients with adenocarcinoma.
引用
- Conrad C, Basso V, Passot G, et al. Comparable long-term oncologic outcomes of laparoscopic versus open pancreaticoduodenectomy for adenocarcinoma: a propensity score weighting analysis. Surg Endosc. 2017. PMID: 28205031. doi:10.1007/s00464-017-5430-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。